According to a new report, published by KBV research, The Global Implantable Cardioverter Defibrillator Market size is expected to reach $5.6 billion by 2030, rising at a market growth of 6.1% CAGR during the forecast period.
The Biventricular Devices segment is generating the highest revenue in the Global Implantable Cardioverter Defibrillator Market, By Type in 2022; thereby, achieving a market value of $2.5 billion by 2030. Biventricular devices treat heart failure, specifically in patients with reduced left ventricular function. These devices can increase the heart's pumping effectiveness by coordinating the ventricles' contractions, which reduces symptoms of heart failure like fatigue, fluid retention, and shortness of breath.
The Subcutaneous segment is experiencing a CAGR of 9.8% during (2023 - 2030). S-ICDs are implanted under the skin rather than within the blood vessels or the heart. This minimally invasive approach can reduce the risk of complications associated with transvenous ICDs, such as lead-related issues or infections. S-ICDs are leadless, meaning they do not require intravascular leads to be threaded into the heart chambers. This eliminates the risk of lead-related complications, such as lead fractures or infections, which can occur with transvenous ICDs.
The NYHA Class II segment is registering maximum revenue in the Global Implantable Cardioverter Defibrillator Market, By NYHA Class in 2022; thereby, achieving a market value of $3.8 billion by 2030. The expansion of ICD uses for NYHA Class II patients involves identifying individuals at the highest risk of ventricular arrhythmias and sudden cardiac death. Risk stratification tools and criteria are being developed to help healthcare providers identify suitable candidates for ICD implantation. Advances in ICD technology, including more sophisticated arrhythmia detection algorithms and remote monitoring capabilities, have made it possible to tailor therapy to individual patient needs and monitor device function effectively.
The Ambulatory Surgical Centers segment is exhibiting a CAGR of 6.5% during (2023 - 2030). ASCs typically offer a more streamlined and efficient experience for patients. Procedures can be scheduled with minimal waiting times, and patients can often return home on the same day as the procedure, reducing the disruption to their daily lives. Some ASCs provide specialized cardiac care, including ICD implantation. This specialization can lead to high-quality, focused care for patients with cardiac conditions. ASCs adhere to strict infection control protocols, which can help minimize the risk of device-related infections during and after ICD implantation procedures.
The North America region dominated the Global Implantable Cardioverter Defibrillator Market, By Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $2.2 billion by 2030. The Europe region is anticipated to grow a CAGR of 5.7% during (2023 - 2030). Additionally, The Asia Pacific region would witness a CAGR of 6.9% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/implantable-cardioverter-defibrillator-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, Medtronic PLC, Biotronik SE & Co. KG, Boston Scientific Corporation, MicroPort Scientific Corporation, Stryker Corporation, ZOLL Medical Corporation (Asahi Kasei Corporation), LivaNova PLC, Koninklijke Philips N.V. and Getinge AB.
By Type
By Product Type
By NYHA Class
By End-use
By Geography
Companies Profiled
Unique Offerings 
